Can You Use GLP-1 to Lose a Few Pounds? (October 2026)

01 · The core answer

Can you use GLP-1 to lose a few pounds?

Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine made by Eli Lilly. In the UK it is licensed for weight management in adults and for type 2 diabetes.¹ That wording matters. It is a weight-management treatment, assessed by a prescriber for each person.

No one can simply choose the medicine. It is prescription-only, supplied after an online consultation reviewed by a GPhC-registered prescriber, and used alongside a reduced-calorie diet and increased physical activity.¹ The prescriber weighs your BMI, your weight-related health conditions, your medicines and your goals. Where the clinical case is not there, a responsible prescriber will say no.

If you want weight loss medication for a small amount of weight, the key question is not whether the drug can lower the scales. It can. The question is whether the benefit outweighs the side effects, the cost and the commitment. For a small amount of weight in someone with no weight-related health condition, it usually does not.

02 · Eligibility

How a prescriber decides if you are suitable

Prescribers commonly look at BMI. The thresholds usually discussed are a BMI of 30 kg/m² or above, or 27 kg/m² or above alongside a weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. If your BMI sits below those lines, the clinical rationale for a weight-management injection is generally weak, whatever the number on the scales says.

NHS access is stricter and is being phased in. NICE recommends Mounjaro for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first.⁴ Full rollout is expected to take years.

Our free consultation is a short health questionnaire with no charge and no obligation. A GPhC-registered prescriber reviews it, and if they decide the treatment is not suitable, the order is refunded automatically in full. Being declined is a normal and sometimes the safest outcome.

03 · Your next step

What to do next

Work out where you honestly sit. If you have a clinical need, a prescriber can assess you for a licensed treatment. If you are close to a healthy weight and want to lose a little, start with food, protein, movement, sleep and alcohol.

If you do meet the criteria and want to see what treatment involves, you can review the Mounjaro pen, prices and consultation. The 2.5mg starter pen costs £169.99 at the standard price, and new customers save £40 on their first order with code FIRST40. For broader support, see our weight loss clinic.

These medicines are not built for speed. The first weeks are an adjustment phase, and a medicine that works month by month is a poor match for a deadline measured in days.

04 · How GLP-1 works

How GLP-1 medicines work

Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1.¹ Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin. In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.

That last phrase is the point. The medicine does not burn fat on its own. It makes it easier to eat less, and the weight comes off because of the reduced intake. If your eating is already moderate and your weight is close to where you want it, there is less room for the medicine to help, and more room for side effects to feel disproportionate.

This dual action distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide, sold as Wegovy and Ozempic. Both groups are licensed prescription treatments, and a prescriber, not the buyer, chooses between them based on the person in front of them. You can read more in our explainer on why people lose weight on GLP-1 medicines.

Slowed stomach emptying can also affect how quickly some other tablets are absorbed, particularly when you start treatment or increase the dose.

Tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system. There is no way to speed this up, and nothing needs doing while it clears. That matters if you are thinking of a short course. A short course is not really short, because the medicine remains active for weeks after the last injection.

It is also worth understanding what stopping means. These are treatments used alongside lasting changes in eating and activity. Taking one for a brief period to shift a few pounds, then stopping, leaves you with the same appetite you started with, minus the support. That is another reason prescribers tend to reserve them for people with a sustained clinical need.

05 · Realistic pace of results

How fast does it work, realistically?

Weight loss on Mounjaro is gradual by design. The first weeks on 2.5mg are an adjustment phase and losses are usually modest; most measurable progress builds from 5mg onward, month by month.¹ Trials measured results at 72 weeks, so think in months, not days, and judge progress by trend, not individual weigh-ins.²

The starting dose is about letting your body adjust, not about weight loss itself.

Experiences differ widely. Some people notice appetite change and early loss in the first week, others feel little until a higher dose, and both are normal. Early loss includes water weight, so the trend over weeks matters more than any single weigh-in. Mild nausea, altered appetite and tiredness in the first days after each injection are the commonest early effects and usually settle.

Three months in, most people are still on the lower rungs of the dose ladder, so trial-average losses at this stage are modest compared with the headline figures. A sensible expectation at that point is mid single digits as a percentage of body weight, with wide individual variation. Slower early progress does not predict failure, because the dose you respond to may still be ahead of you.

For someone with only a few pounds to lose, this creates an odd situation. The early, modest phase may be the whole of what they need, but they would still be exposed to side effects during titration. That is a heavy process for a small result.

The pattern is the same throughout: steady, trend-based progress rather than dramatic weeks.

Treatment response is also reviewed by your prescriber. If you have lost less than 5% of your starting weight after 6 months on the highest dose you can tolerate, your prescriber will discuss whether continuing or stopping is right for you.⁴ That review structure exists because the medicine is meant to deliver a worthwhile clinical benefit, not simply any movement on the scales.

06 · What the trials show

What the trial results actually mean

In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages, individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.

Read those numbers carefully. They describe what happened in adults who had a clinical need for weight management and who stayed in a long programme. They do not describe a quick trim. They also do not tell you what will happen to you, because trial averages do not predict your own result.

For a worked example, someone starting at 100 kg who matched the 15mg average of 20.9% would lose about 21 kg. That is a large change in body weight, and it is what the medicine is designed for. It is not a small adjustment, and the trial population was not people looking for a few pounds.

At 72 weeks, 85% of participants on 5mg, 89% on 10mg and 91% on 15mg had lost at least 5% of their body weight. Half of participants on 10mg and 57% on 15mg lost at least 20% of their body weight.² These figures show the treatment is effective for people with obesity-level need. They say nothing about whether it is sensible for someone who is only slightly above their target.

Beyond the scales, weight loss on tirzepatide came with average improvements in waist size, blood pressure, cholesterol and blood-sugar measures, and most participants with prediabetes returned to normal blood-sugar levels.² These are trial-average secondary outcomes rather than promises, but they are why prescribers talk about weight management as health management rather than appearance. A person with no weight-related health problems has less to gain on this front.

The takeaway is not that the medicine is weak. It is that the evidence base is built on people with a clinical reason to be treated, and the risk-benefit balance in that group is different from the balance in someone who wants to lose a little. Good prescribing respects that difference.

If you want to compare how different people and goals map onto timelines, the page on how long larger losses take on Mounjaro shows how the same trial figures are used with worked examples, and always with the caveat that your own result may differ.

07 · Eligibility and the NHS

Eligibility: private prescribing and the NHS

Eligibility is the real answer to most versions of this question. A prescriber needs a clinical reason to treat, and the licence frames the medicine as weight management for adults. When someone asks whether they can use a GLP-1 medicine for a few pounds, what they are really asking is whether they would pass an assessment. For many people in that position, they would not.

Private prescribers commonly work to BMI thresholds of 30 kg/m², or 27 kg/m² with a weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. Those lines are not arbitrary. They separate people where the likely health benefit justifies the treatment from people where it generally does not. Someone at a BMI below 27 is unlikely to be offered treatment, and a prescriber who agreed without a clinical reason would be failing their duty of care.

Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first, initially BMI 40+ with four or more qualifying conditions.⁴⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

If you are below those thresholds, the NHS will not be the route for a small loss, and you should not expect private treatment to be either. That is not gatekeeping for its own sake.

What if you are unsure where you sit? Check your BMI honestly, note any conditions you have been diagnosed with, and bring both to the consultation. A GPhC-registered prescriber reviews every submission, and our process is free, with no obligation to proceed. If you are declined, you are refunded automatically in full.

Finally, be wary of anyone offering to supply a prescription medicine without a consultation or prescription. A proper assessment is part of the safety of treatment, not an obstacle to it. The regulator for pharmacies lists registered services, and ours is on the GPhC register under 9012878.

08 · Side effects and interactions

Side effects and medicine interactions

The honest trade-off sits here. Mild nausea, altered appetite and tiredness in the first days after each injection are the commonest early effects and usually settle.¹ For someone with a significant clinical need, that is an acceptable price. For someone who wants to lose a few pounds, even mild but repeated nausea can feel like a poor exchange.

The full list of effects is in the patient information leaflet supplied with the medicine. Our prescribing team also provides side-effect support as part of monthly reviews. If you have a new symptom you are unsure about, discuss it with your prescriber, and you can report suspected side effects through the MHRA Yellow Card scheme.¹⁹

Because Mounjaro slows stomach emptying, it can affect how quickly some oral medicines are absorbed, particularly when you start treatment or increase the dose. Tell your prescriber about everything you take, especially warfarin or other narrow-margin medicines, insulin, or sulfonylureas, where doses may need reducing to avoid low blood sugar. No adjustment is needed for paracetamol.¹

Contraception deserves a mention. The medicine can reduce absorption of oral contraceptives because stomach emptying slows. The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.¹ Raise it in your consultation if it applies to you.

Weigh all of this against the goal. If the aim is a small change in weight, a prescriber will weigh the downsides carefully. That is exactly the judgement a prescriber is there to make with you, and it is why a free consultation is a sensible first step rather than a formality.

One more practical point: a prescription medicine should never be sourced from sellers who skip the assessment. Counterfeit and unregulated products are a genuine hazard, and MHRA publishes alerts on them.⁷ Our Mounjaro comes through official LillyDirect supply, as genuine KwikPens direct from Eli Lilly's UK distribution.

09 · Doses and shortcuts to avoid

Dose ladder, and shortcuts to avoid

Everyone starts Mounjaro on 2.5mg once a week. This starting dose is about letting your body adjust, not about weight loss itself. After at least four weeks the dose increases to 5mg, and can then step up by 2.5mg at minimum four-week intervals, through 7.5mg, 10mg and 12.5mg, up to a maximum of 15mg weekly, depending on how you respond and tolerate it.¹ Many people settle at a maintenance dose of 5mg, 10mg or 15mg. Higher is not automatically better, and your prescriber will guide the right pace.

A common thought for people with a small goal is to use less. Altering doses outside the licence means unknown dosing accuracy and no safety data.

Injection is under the skin once a week, on the same day each week, at any time of day, with or without food. Rotate the site with each dose. There is no best time of day, and what matters is consistency.

If you miss a dose, take it as soon as you can within four days of the scheduled time. If more than four days have passed, skip it and take the next on your normal day, and never take two doses within three days of each other. You can change your weekly injection day as long as at least three days have passed since your last dose.

Storage is simple. Keep pens in a fridge at 2–8°C and never freeze them. Once in use, a pen can be kept out of the fridge not above 30°C for up to 30 days, after which it should be discarded.

None of this rewards experimenting. The dose structure is built for people with a clinical need, and bending it to fit a small goal creates risk without a matching benefit.

10 · Losing the last few pounds

What works for the last few pounds

For a small amount of weight, the dependable tools are ordinary ones. Start with an honest look at intake, because portions drift upwards without anyone noticing. Keep a simple record for a couple of weeks, and compare it with what you thought you ate. The gap is often where the weight sits.

Protein matters, because it helps fullness and supports muscle while you eat less. Build meals around lean cuts, eggs, fish, pulses or dairy, and add vegetables for volume. Alcohol is another quiet contributor, since it adds energy without filling you, and sleep affects appetite the next day. These are the basics, and they are the same ones a prescriber would ask you to check even if you were on a medicine.

Activity helps in two ways. It adds to energy use, and it protects strength. Choose something you will actually repeat, such as walking, cycling or resistance sessions, and make it routine rather than heroic.

If you are already on treatment and have stalled, the guidance is clear. Weight loss on Mounjaro is not linear, and plateaus of a few weeks are normal and expected as the body adapts to a lower weight. Within the licence, the responses are to review food intake honestly, protect protein and activity, check the basics such as sleep and alcohol, and discuss with your prescriber whether a dose step-up is appropriate if you are not yet at maximum. A plateau is not a reason to double doses or add unlicensed products.¹

Be sceptical of low-cost supplements sold as natural alternatives to prescription weight-loss medicines. They are available cheaply without assessment and carry no clinical oversight, and their dosing is not standardised. Dramatic weight-loss claims in their marketing should be treated with caution, and none of them are the same as a licensed medicine.

Finally, if your goal is to lose weight because of a health concern rather than appearance, that is a different conversation. Speak to your GP or start a free consultation, where a prescriber can look at your BMI and conditions together and tell you plainly whether treatment is appropriate.

11 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹

12 · Ordering and aftercare

If you do meet the criteria: how ordering works

If a prescriber confirms you are suitable, the process is straightforward and transparent. First is a free online consultation, which is a short health questionnaire with no charge and no obligation. Second, a GPhC-registered prescriber reviews it, not a scoring script. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.

Third, your order is dispensed by our registered pharmacy, with same-day dispatch when ordered by 3pm. Fourth, delivery is free, next-day and tracked through DPD, in temperature-controlled, discreet packaging. Saturday delivery is £14.99.

The consultation is free, the price shown is the price paid, and there are no hidden fees. All six doses, 2.5mg to 15mg, are in stock, and we supply genuine KwikPens through official LillyDirect supply. Needles, a sharps bin and injection guidance come with every order.

On cost, the standard price of the 2.5mg pen is £169.99. Your first 2.5mg pen costs £129.99 with code FIRST40, and every later order is £25 off the standard price with code DOSE25. Prices were checked 11 October 2026. If you step up after 4 weeks on each dose, your first four pens (2.5mg to 10mg) cost £959.96 at standard prices. Separately, a first year costs £2,711.88 if you stay on 5mg after your 2.5mg starting pen, up to £3,599.88 if you step up through every dose to 15mg; a new customer's first order is £40 less and every later order £25 less.

Aftercare includes ongoing monthly reviews, dose-titration and follow-up assessments by the prescribing team, and side-effect support. Repeat orders re-check suitability, with no auto-shipping and no subscriptions. You can pay by Visa or Mastercard, with Klarna and pay-monthly options also available.

Our free GLPTrackr companion app helps you log your journey, so you judge progress by trend rather than a single weigh-in. If you are thinking about a much larger goal, the page on how long major weight loss takes on Mounjaro gives a realistic view of the commitment involved. Support is available Monday to Friday, 9am to 5pm, by email at support@everydaymeds.co.uk, in your account portal chat, or by phone on 0333 207 0413.

Mounjaro (tirzepatide) is a prescription-only medicine, supplied only after an online consultation reviewed by a GPhC-registered prescriber. It is used alongside a reduced-calorie diet and increased physical activity. Individual results vary. This page is information, not a substitute for medical advice.